An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

We have previously reported the establishment of a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype. The strain was generated in vitro by serial daptomycin selection (Camargo, I. L., H. M. Neoh, L. Cui, and K. Hiramatsu, Antimicrob. Agents Chemother. 52:4289-4299, 2008). Here we explored the genetic mechanism of resistance in the strain by whole-genome sequencing and by producing gene-replaced strains. By genome comparison between 10 3d1 and its parent methicillin-resistant Staphylococcus aureus (MRSA) strain N315ΔIP, we identified five nonsynonymous single nucleotide polymorphisms (SNPs). One of the five mutations was found in the rpoB gene encoding the RNA polymerase β subunit. The mutation at nucleotide position 1862 substituted the 621st alanine by glutamic acid. The replacement of the intact rpoB with the mutated rpoB, designated rpoB(A621E), conferred N315ΔIP with the phenotypes of reduced susceptibility to daptomycin and hetero-VISA. The rpoB(A621E)-mediated resistance conversion was accompanied by a thickened cell wall and reduction of the cell surface negative charge. Being consistent with these phenotypic changes, microarray data showed that the expression of the dlt operon, which increases the cell surface positive charge, was enhanced in the rpoB(A621E) mutant. Other remarkable findings of microarray analysis of the rpoB(A621E) mutant included repression of metabolic pathways of purine, pyrimidine, arginine, the urea cycle, and the lac operon, enhancement of the biosynthetic pathway of vitamin B2, K1, and K2, and cell wall metabolism. Finally, mutations identified in rplV and rplC, encoding 50S ribosomal proteins L22 and L3, respectively, were found to be associated with the slow growth, but not with the phenotype of decreased susceptibility to vancomycin and daptomycin, of 10 3d1.

Knowledge Graph

Similar Paper

An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2010.0
Serial Daptomycin Selection Generates Daptomycin-NonsusceptibleStaphylococcus aureusStrains with a Heterogeneous Vancomycin-Intermediate Phenotype
Antimicrobial Agents and Chemotherapy 2008.0
Mutated Response Regulator graR Is Responsible for Phenotypic Conversion of Staphylococcus aureus from Heterogeneous Vancomycin-Intermediate Resistance to Vancomycin-Intermediate Resistance
Antimicrobial Agents and Chemotherapy 2008.0
Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced Vancomycin Susceptibility Is Independent of Alterations in MprF
Antimicrobial Agents and Chemotherapy 2007.0
Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2009.0
Genomic Analysis Reveals a Point Mutation in the Two-Component Sensor Gene graS That Leads to Intermediate Vancomycin Resistance in Clinical Staphylococcus aureus
Antimicrobial Agents and Chemotherapy 2008.0
Cell Wall Thickening Is Not a Universal Accompaniment of the Daptomycin Nonsusceptibility Phenotype in Staphylococcus aureus : Evidence for Multiple Resistance Mechanisms
Antimicrobial Agents and Chemotherapy 2010.0
Stepwise Exposure of Staphylococcus aureus to Pleuromutilins Is Associated with Stepwise Acquisition of Mutations in rplC and Minimally Affects Susceptibility to Retapamulin
Antimicrobial Agents and Chemotherapy 2007.0
A mec A -Negative Strain of Methicillin-Resistant S taphylococcus aureus with High-Level β-Lactam Resistance Contains Mutations in Three Genes
Antimicrobial Agents and Chemotherapy 2010.0
Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
Antimicrobial Agents and Chemotherapy 2009.0